Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06208748 · ClinicalTrials.gov registry record · Phase 2
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
A Phase 2 study of Gastrointestinal Stromal Tumors and GIST, sponsored by Sarcoma Alliance for Research through Collaboration.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT06208748 is a Phase 2 study of Gastrointestinal Stromal Tumors and GIST that is active but no longer recruiting, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 40 participants, below the 91-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (56% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06208748, a Phase 2 study of Gastrointestinal Stromal Tumors and GIST, is active but no longer recruiting, sponsored by Sarcoma Alliance for Research through Collaboration.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Conditions Studied
Interventions
- DRUG Bezuclastinib in combination with sunitinib
Study Locations (4)
Florida
- Sylvester Comprehensive Cancer Center, University of Miami - Miami
Massachusetts
- Dana Farber Cancer Institute - Boston
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06208748
The ClinicalTrials.gov registry entry for NCT06208748 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (56% lower). The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastrointestinal Stromal Tumors appearing as the primary indexed condition, and to 1 intervention - of which Bezuclastinib in combination with sunitinib is the first listed.
NCT06208748 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Massachusetts, Oregon.
Frequently Asked Questions
What is clinical trial NCT06208748 about?
NCT06208748 is a clinical study titled "SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST". This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
What is the current status of trial NCT06208748?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-08-01. Estimated completion is 2027-06.
What conditions does trial NCT06208748 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumors, GIST.
What interventions are being tested in trial NCT06208748?
The interventions under investigation include: Bezuclastinib in combination with sunitinib (DRUG).
Who is sponsoring clinical trial NCT06208748?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06208748 being conducted?
This trial has 4 study locations across Florida, Massachusetts, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
RECRUITING · Phase 2
-
Imatinib TDM in GIST
RECRUITING · Phase 2
-
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
COMPLETED · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.